SYDNEY, OCTOBER 2018
NeuClone Announces First Human Dose of Herceptin® (Trastuzumab) Biosimilar Candidate in Phase I Clinical Trial
SYDNEY, MAY 2018
NeuClone Announces Preclinical Results for Stelara (ustekinumab) Biosimilar Candidate
SYDNEY, JANUARY 2018
NeuClone discloses details of its fifth product: a biosimilar candidate for Prolia®/XGEVA®
BERLIN, NOVEMBER 2017
NeuClone attends the 23rd International Partnering Conference BIO-Europe
LAUSANNE, MAY 2017
NeuClone presents at the 25th ESACT Meeting
SAN FRANCISCO, JANUARY 2017
NeuClone attends the 35th Annual J.P. Morgan Healthcare Conference
COLOGNE, NOVEMBER 2016
NeuClone presents at the 22nd Annual BIO-Europe Conference
SYDNEY, AUGUST 2016
US patent granted for NeuCHO®, NeuClone’s robust cell expression system
SAN FRANCISCO, JUNE 2016
Dr. Angelo Perani presents at the 12th annual Cell Line Development and Engineering conference
SAN FRANCISCO, JUNE 2016
Dr. Russell Howard, John Oksinski and Dr. Noelle Sunstrom attend the BIO International Convention
PALM SPRINGS, MAY 2016
Dr. Noelle Sunstrom attends Cell Culture Engineering XV
SYDNEY, OCTOBER 2015
The Hon Sussan Ley MP, Minister of Health, officially opens NeuClone’s new biomanufacturing facilities